NeoGenomics (NASDAQ:NEO - Free Report) had its price objective increased by TD Cowen from $10.00 to $12.00 in a report released on Friday,Benzinga reports. They currently have a buy rating on the medical research company's stock.
Other equities research analysts also recently issued reports about the company. Morgan Stanley set a $8.00 price objective on NeoGenomics and gave the stock an "equal weight" rating in a report on Wednesday, July 30th. Stephens boosted their price target on NeoGenomics from $6.50 to $11.00 and gave the company an "overweight" rating in a report on Tuesday, September 2nd. Needham & Company LLC boosted their price target on NeoGenomics from $8.00 to $14.00 and gave the company a "buy" rating in a report on Friday, August 29th. William Blair reissued a "market perform" rating on shares of NeoGenomics in a report on Tuesday, July 29th. Finally, BTIG Research reissued a "neutral" rating on shares of NeoGenomics in a report on Wednesday, July 30th. Seven research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, NeoGenomics presently has an average rating of "Hold" and a consensus target price of $13.10.
Get Our Latest Research Report on NeoGenomics
NeoGenomics Stock Up 3.8%
NASDAQ:NEO traded up $0.31 during trading hours on Friday, reaching $8.30. 2,187,076 shares of the company traded hands, compared to its average volume of 2,052,970. The business's 50-day moving average price is $6.78 and its two-hundred day moving average price is $7.86. The stock has a market capitalization of $1.07 billion, a P/E ratio of -10.39 and a beta of 1.62. NeoGenomics has a 1 year low of $4.72 and a 1 year high of $19.11. The company has a current ratio of 3.92, a quick ratio of 3.58 and a debt-to-equity ratio of 0.40.
Institutional Trading of NeoGenomics
Several hedge funds and other institutional investors have recently bought and sold shares of NEO. Squarepoint Ops LLC boosted its position in shares of NeoGenomics by 246.8% in the 2nd quarter. Squarepoint Ops LLC now owns 735,473 shares of the medical research company's stock worth $5,376,000 after purchasing an additional 523,407 shares in the last quarter. State of Wyoming boosted its position in shares of NeoGenomics by 243.1% in the 2nd quarter. State of Wyoming now owns 13,899 shares of the medical research company's stock worth $102,000 after purchasing an additional 9,848 shares in the last quarter. Public Sector Pension Investment Board boosted its position in shares of NeoGenomics by 7.8% in the 2nd quarter. Public Sector Pension Investment Board now owns 438,762 shares of the medical research company's stock worth $3,207,000 after purchasing an additional 31,745 shares in the last quarter. FORA Capital LLC acquired a new stake in shares of NeoGenomics in the 2nd quarter worth $84,000. Finally, Headlands Technologies LLC acquired a new stake in shares of NeoGenomics in the 2nd quarter worth $32,000. Institutional investors own 98.50% of the company's stock.
NeoGenomics Company Profile
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Read More
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
